Literature DB >> 8961143

Optimizing the lyophilization cycle and the consequences of collapse on the pharmaceutical acceptability of Erwinia L-asparaginase.

G D Adams1, J R Ramsay.   

Abstract

The antileukemia enzyme, Erwinia L-asparaginase, occurs as a tetramer which can be dissociated by the stresses of lyophilization into four subunits (subunit M(r) 34 000 Da). Dissociation can be reduced by adding protectants to the formulation to stabilize the biopolymer, while the product should dry to form a pharmaceutically elegant, shelf-stable cake which is readily soluble. Using analytical ultracentrifugation, HPLC, and circular dichroism we have related structural dissociation of the enzyme during lyophilization to biological activity. Additives such as mannitol prevent ablation loss of vial contents and dry to form cosmetically elegant cakes but provide little biological protection, since during freezing they crystallize and are removed from the preparation. Excipients persisting throughout the cycle in the amorphous state provide improved biological protection, although high molecular weight compounds such as Dextran (M(r) 70000 Da) are most effective only during product freezing or storage. Low molecular weight sugars are protective throughout the cycle although formulations containing monosaccharides often exhibit low collapse temperatures (Tc) measured using a freeze-drying microscope or glass transition temperatures (Tg') measured by thermal analysis, but these formulations distort as drying progresses to form a collapsed, cosmetically unacceptable cake, with reduced activity, poor stability, a high moisture content, and reduced solubility. Collapse can be avoided by formulating with disaccharides, which display higher Tc temperatures than monosaccharides, or drying below Tc. Dried samples which persist in the amorphous state can also collapse when stored above their solid-state collapse temperatures when they decay at a faster rate than predicted by Arrhenius kinetics. The solid-state collapse temperature can be significantly decreased by the diffusion of moisture from the stopper into the dry product resulting in an increase in sample water content. Lyophilization cycle times can be reduced by analyzing collapse characteristics so that the relationship between product temperature and chamber pressure can be controlled so that drying rates can be optimized while ensuring that the product does not melt or collapse during sublimation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961143     DOI: 10.1021/js960146p

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Effect of sugars, surfactant, and tangential flow filtration on the freeze-drying of poly(lactic acid) nanoparticles.

Authors:  Samuli Hirsjärvi; Leena Peltonen; Jouni Hirvonen
Journal:  AAPS PharmSciTech       Date:  2009-04-21       Impact factor: 3.246

2.  Detection of Collapse and Crystallization of Saccharide, Protein, and Mannitol Formulations by Optical Fibers in Lyophilization.

Authors:  Jacqueline Horn; Wolfgang Friess
Journal:  Front Chem       Date:  2018-01-26       Impact factor: 5.221

3.  Shelf-Life Evaluation and Lyophilization of PBCA-Based Polymeric Microbubbles.

Authors:  Tarun Ojha; Vertika Pathak; Natascha Drude; Marek Weiler; Dirk Rommel; Stephan Rütten; Bertram Geinitz; Mies J van Steenbergen; Gert Storm; Fabian Kiessling; Twan Lammers
Journal:  Pharmaceutics       Date:  2019-08-26       Impact factor: 6.321

4.  Thermal resilience of ensilicated lysozyme via calorimetric and in vivo analysis.

Authors:  A Doekhie; M N Slade; L Cliff; L Weaver; R Castaing; J Paulin; Y-C Chen; K J Edler; F Koumanov; K J Marchbank; J M H van den Elsen; A Sartbaeva
Journal:  RSC Adv       Date:  2020-08-12       Impact factor: 4.036

5.  Evaluation of Packaging Materials in Freeze-Drying: Use of Polymer Caps and Nested Vials and Their Impact on Process and Product Attributes.

Authors:  Tim Wenzel; Henning Gieseler
Journal:  AAPS PharmSciTech       Date:  2021-02-23       Impact factor: 3.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.